CRISPR-Cas9 for the genome engineering of cyanobacteria and succinate production (Li et al, 2016).
Bioethics, legal implications and perspective in Colombia
In May 2015, the researchers rumored that genetic editing was being done on human embryos, and so the Liang group and colleagues in China made that first essay(Bermudez & Lizarazo-Cortés, 2016).
​
The experiment uses tripronuclear zygotes, that is, fertilized by two sperm instead of one, and the zygotes are "made in the laboratory" (Liang et al., 2015). These begin the cell division but do not exceed the stage of 14 days of development, so the researchers postulated that they are a good model for the study of genetic editing. This event led to a cascade of events that brought together the scientific community, which is now taking its first steps in terms of criteria for regulation (Bermudez & Lizarazo-Cortés, 2016).
Read more
Bermudez, N., & Lizarazo-Cortés, Ó. (2016). Técnica de edición de genes crispr ⁄ cas9. Retos jurídicos para su regulación y uso en Colombia. La Revista Inmaterial, 79–110.
Geneticist Jennifer Doudna co-invented a groundbreaking new technology for editing genes, called CRISPR-Cas9. The tool allows scientists to make precise edits to DNA strands, which could lead to treatments for genetic diseases … but could also be used to create so-called "designer babies." Doudna reviews how CRISPR-Cas9 works — and asks the scientific community to pause and discuss the ethics of this new tool.